Prowse

Dr David Prowse

BSc PhD
Centre: Director's Office
Fellowships:
Research Council UK, Academic Fellowship
Job Title: Senior Lecturer
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Research Interests


Dr David Prowse's main research themes are in: Genitourinary Cancer and Prostate Cancer


The main focus of my research is to understand and target the molecular events involved in the development and progression of prostate and penile cancer. In particular, my studies focus on the identification and functional analysis of prostate and penile cancer biomarkers, the development and treatment of androgen independent prostate cancer, the role of prostate cancer cells with stem cell characteristics and the analysis of prostate circulating tumour cells enabling non-invasive diagnosis and monitoring of clinical trial patients.

These approaches have significant potential for improving survival and quality of life for male cancer patients.

Profile

I joined the Barts Cancer Institute in July, 2007.

I completed my BSc at the University of Bath (1989) and my PhD at the CR-UK Beatson Institute for Cancer Research / University of Glasgow (1993).

After postdoctoral experience at the Cutaneous Biology Research Center, Harvard Medical School / Massachusetts General Hospital, USA (1993-1999) and the CR-UK Keratinocyte Laboratory, London Research Institute (1999-2003) I established my own research group in the Centre for Cutaneous Research, Institute of Cell and Molecular Science at the Barts and The London School of Medicine and Dentistry in July 2003, moving to the Centre for Molecular Oncology, Barts Cancer Institute in July 2007.

Since 2003 I have been involved with a cancer research programme with particular interest in prostate and penile cancer. In 2010 I have had responsibility for administration and delivery of undergraduate Cancer teaching.

Funding

  • Research Council UK: Academic Fellowship 2005-2010 £125,000
  • Barts and The London Charitable Foundation: Post-doctoral grant 2006-2008 £97,000
  • Orchid Cancer Appeal: Programme grant 2007-2008 £154,893
  • Orchid Cancer Appeal: Programme grant 2006-2007 £178,596
  • Orchid Cancer Appeal: Programme grant 2005-2006 £199,832
  • Orchid Cancer Appeal: Programme grant 2004-2005 £187,523
  • Orchid Cancer Appeal: Programme grant 2003-2004 £163,593

Key Publications

Papers since 2008:

Alternative pathways of AKT pathway activation in HPV positive and negative penile carcinomas. Stankiewicz E, Prowse DM, Ng M, Cuzick J, Mesher D, Hiscock F, Lu Y-J, Watkin N, Corbishley C, Lam W, Berney DM. PLOS One (2011) In press

Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer. Kudahetti SC, Fisher G, Ambroisine L, Prowse DM, Kattan MW, Foster CS, Møller H, Oliver T, Fletcher A, Cooper C, Reuter V, Scardino P, Cuzick J, Berney DM; Transatlantic Prostate Group. Pathology. 2010;42(6):519-23. PMID: 20854069

HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Stankiewicz E, Kudahetti SC, Prowse DM, Ktori E, Cuzick J, Ambroisine L, Zhang X, Watkin N, Corbishley C, Berney DM. Mod Pathol. (2009) 22(9),1160-8. PMID: 19465901

WNT signalling affects self-renewal and differentiation of androgen independent human prostate cancer stem cells. Bisson I, Prowse DM. Cell Research. (2009) 19(6):683-97. PMID: 19365403

Human papillomavirus is detected in transitional cell carcinoma arising in renal transplant recipients. Husain E, Prowse DM, Ktori E, Shaikh T, Yaqoob M, Junaid I, Baithun S. Pathology. 2009;41(3):245-7.

Human papillomavirus-associated increase in p16INK4A expression in penile lichen sclerosus and squamous cell carcinoma. Prowse DM, Ktori EN, Chandrasekaran D, Prapa A, Baithun S. Br J Dermatol. (2008) 158, 261-265.

Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Mao X, Shaw G, James SY, Purkis P, Kudahetti SC, Tsigani T, Kia S, Young BD, Oliver RT, Berney D, Prowse DM, Lu YJ.  Asian Journal Andrology. (2008) 10, 467-73.

Inhibition of androgen independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling. Shaw G, Prowse DM.  Cancer Cell International. (2008) 18;8:3

Hedgehog signalling in androgen independent prostate cancer. Shaw G, Price AM, Ktori E, Bisson I, Purkis PE, McFaul S, Oliver RT, Prowse DM. Eur Urol. 54(6):1333-43. (2008)


Further Publications

For additional publications, please click here.

External Activities

School Science, Technology, Engineering and Mathematics Ambassador.